In recent years, microdosing has become popular as a wellness trend, both in the United States as well as overseas in countries such as Australia. Microdosing involves consuming a low dose of a psychedelic drug to reduce anxiety and stress or boost performance.
While there have been some accounts by consumers who sing the praises of psychedelics, questions about how much of the reported benefits stem from the substances’ pharmacological effects rather than the partaker’s expectations and beliefs, and how microdosing works, still remain.
To help answer some of these questions, we’ll look at a few studies on microdosing and highlight what they uncovered during their research. Research on psychedelics in Australia has advanced speedily, with many studies focusing on the science of microdosing. It is also evident that more Australians are experimenting with psychedelics, as the proportion of adults in Australia who have used psychedelics in their lifetime grew to 10.9% in 2019 from 8% in 2001.
An earlier study conducted by a researcher Vince Polito found that after a six-week period of microdosing, levels of stress and depression in some users were found to have reduced. The participants also admitted that their mind wandered less, which suggests that microdosing causes improved cognitive performance. Conversely, the research findings also note that there was a surge in neuroticism.
Another recent study, led by Stephen Bright, recruited participants who took part in both yoga and microdosing; the study also included participants who did neither of the two. The researchers found that yoga practitioners had higher levels of anxiety and stress in comparison with individuals who practiced microdosing and those who did not engage in microdosing or yoga. They also found that those who engaged in microdosing had higher levels of depression.
When compared to the control group though, the researchers found that both the microdosing and yoga group recorded higher overall scores on psychological well-being. Additionally, those who took part in both microdosing and yoga reported lower levels of stress, anxiety and depression, which suggests that yoga and microdosing may have synergistic effects.
Another study, conducted in collaboration with Germany’s University of Göttingen, Macquarie University and Edith Cowan University, discovered an increase in conscientiousness and a reduction in neuroticism in the 76 study participants who engaged in microdosing. The findings were reported in the “Journal of Psychedelic Studies.”
While there is still much that is unknown about psychedelics and microdosing, these studies provide a level of insight into what one may expect when taking psychedelics under supervision, which may help ease users’ minds.
Researchers hope that in the future, scientific results on microdosing will be less mixed and more valid so that a clearer way forward can be determined.
These researchers’ hopes could be answered sooner than they think as a number of companies, such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), are currently engaged in studying several psychedelic drug formulations for use in treating various ailments, particularly mental health conditions.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.